Pre-made Afutuzumab biosimilar ( Whole mAb, anti-MS4A1 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-013
Anti-MS4A1 therapeutic antibody (Pre-made Afutuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Obinutuzumab (called afutuzumab until 2009) is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-MS4A1 therapeutic antibody (Pre-made Afutuzumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||3pp3:HL:IK/3pp4:HL|
|99% SI Structure||6y9a:HL|
|95-98% SI Structure||6y97:HL|
|Companies||GLYCART Biotechnology;Biogen Idec;Chugai Pharmaceutical;Dana-Farber Cancer Institute;Genentech;Lymphoma Academic Research Organisation;Nippon Shinyaku;OHSU Knight Cancer Institute;Pharmacyclics;Polish Myeloma Consortium;Roche;Thomas Jefferson University;University of Heidelberg;University of Leeds|
|Conditions Approved||Chronic lymphocytic leukaemia;Follicular lymphoma;Non-Hodgkin's lymphoma|
|Conditions Active||Diffuse large B cell lymphoma;CNS cancer;Graft-versus-host disease;Lupus nephritis;Mantle-cell lymphoma;Waldenstrom's macroglobulinaemia|
|Conditions Discontinued||Primary biliary cirrhosis|
|Development Tech||GlycoMAb Technology|